BIO Applauds the Inclusion of Important Health Care and Agriculture Priorities and Programs in Year-end Government Funding Bill

BIO Applauds the Inclusion of Important Health Care and Agriculture Priorities and Programs in Year-end Government Funding Bill

John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), today released the following statement ahead of an expected vote in the U.S. House of Representatives on a year-end government funding bill that includes many urgent and bipartisan health care and agricultural priorities and programs: 


“Congress now has a pivotal opportunity to pass reforms and to authorize funding for programs that will make a meaningful difference to advance the health and well-being of the American people. This bipartisan health care agreement advances policies that will also strengthen American competitiveness in biotechnology, improve our response to future pandemics and help to make life-saving medicines more affordable. 


“The agreement includes bipartisan reforms that will bring more transparency to pharmacy benefit managers (PBMs), middlemen who add wasteful costs to the healthcare system. Advancing these PBM reforms will begin to break the pernicious link between the fees that PBMs charge and the cost of medicines. Now is the time to take these important steps toward improving access to prescription medicines for patients, employers and taxpayers. 


“The legislation further renews a vitally important law that has helped our nation prepare and respond to public health emergencies. It also extends the Pediatric Priority Review Voucher (PPRV) program until September 2029. This program is a market-based mechanism that has incentivized the development of dozens of new treatments for patients with the most rare and devastating pediatric diseases. I’d like to offer a special thank you to the countless patient advocates who worked with us and others to ensure that the PPRV program was reauthorized.


“Additionally, the extension of the farm bill provides critical support to American farmers, ranchers and innovators, and enables continued research, development and sustainability of our nation’s food and renewable fuel supply.


“We urge lawmakers to support these important policies and programs. We look forward to working with the new Congress and new Trump administration to build upon these reforms in the coming year.”

January 20, 2026
January 20, 2026. Paulding County has been designated a BioReady Silver Community by Georgia Life Sciences, the state’s leading life sciences membership organization. The BioReady designation recognizes communities that demonstrate strong zoning practices, infrastructure capacity, and readiness to support biotechnology and life sciences development. “We are proud to recognize Paulding County as our newest BioReady Silver community,” said Maria Thacker-Goethe, President and CEO of Georgia Life Sciences. “Paulding County’s proactive planning, growing workforce, and access to regional healthcare and transportation infrastructure position it well to support life sciences manufacturing and commercialization. Through the BioReady program, we champion communities that are intentionally preparing to compete for industry investment and job growth.” Paulding County’s designation reflects its commitment to thoughtful land-use planning, scalable infrastructure, and business-friendly development policies that support life sciences and advanced manufacturing uses. Located in the northwest Atlanta metro region, the county offers access to a strong labor pool, major transportation corridors, and regional healthcare systems, making it an attractive option for biotechnology, medical device, diagnostics, and related life sciences companies seeking room to grow. “Georgia BioReady designation validates Paulding County’s readiness to support bioscience investment and strengthens our position as a growing hub for advanced industries,” said Alex Almodovar, President & CEO, Paulding County Economic Development Inc. & Industrial Building Authority The BioReady rating system evaluates communities across three tiers—Bronze, Silver, and Gold—based on their readiness to attract and support life sciences facilities. Through these ratings, Georgia Life Sciences helps municipalities better showcase biotech-appropriate sites, strengthen infrastructure planning, and clearly identify life sciences-friendly locations. This approach enables communities like Paulding County to compete more effectively for private investment and high-quality job creation. Georgia Life Sciences advances innovation, strengthens the workforce pipeline, and grows Georgia’s life sciences economy through the BioReady Community program, modeled after MassBio’s nationally recognized rating system, which assesses a community’s readiness to host life sciences facilities based on zoning practices and infrastructure capacity. About Georgia Life Sciences Georgia Life Sciences, founded in 1989, is a non-profit, membership-based organization that promotes the interests and growth of the life sciences industry. It is the state’s largest and most influential life sciences advocacy and business leadership organization working to improve access to innovative discoveries that have lifesaving impact. The association connects business, academia, government, and other allied entities involved in the application of life sciences products to fuel growth and collaboration through policy development, community programs, national industry initiatives, and a portfolio of educational and networking events. Learn more at galifesciences.org.
January 14, 2026
What happens when students see real work before choosing a future 
January 8, 2026
By: Patrick Plues | RealClearHealth January 8, 2026 For decades, America has led the global biotech industry – thanks, in part, to state-level policies that encourage research and manufacturing investments. But other countries, including China, are sparing no expense in the bid to overtake us. Beijing has officially made biotechnology a national strategic priority and is pouring billions into state-backed research and manufacturing efforts. All states should consider impactful biotech policies that grow and strengthen our domestic biotechnology industry. If states fail to utilize and replicate what are considered to be the best and most successful policies in biotech-focused economic development, the United States will soon lose its long-term leadership in developing medicines and medical technologies, which underpin our health, our economy, and our national security. Thankfully, many governors and state legislatures around the country are already answering this call -- as our new study, The U.S. Bioscience Industry: A Powerful Engine for State Economies, demonstrates. Keep Reading at https://www.realclearhealth.com/2026/01/08/americas_biotech_leadership_depends_on_the_states_1157584.html
MORE POSTS